IRISYS
28.7.2020 12:02:09 CEST | Business Wire | Press release
The COVID-19 pandemic has created an urgent need to accurately and efficiently manage occupancy regulations and enable social distancing in corporate workspaces, higher education buildings, retail stores, and manufacturing facilities. The Irisys SafeCount™ Live Occupancy Monitoring Solution helps businesses comply with social distancing and occupancy guidelines by anonymously counting people as they enter and exit buildings and rooms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200728005318/en/
Suitable for buildings of all sizes, even those with multiple entrances and exits, SafeCount delivers live occupancy data with visual warnings and alerts when limits are approached or exceeded.
Built on the advanced Irisys Vector 4D people counting sensor, SafeCount features:
- Easy, fast installation — Simple setup and configuration in less than 30 minutes.
- Highly accurate — Better than 99 percent sensor accuracy that is unaffected by environmental conditions or large crowds.
- Privacy protection — no personally identifiable information is captured by the system.
- Staff detection — advanced functionality can exclude staff from occupancy count.
- Standalone system, yet scalable — SafeCount works separately from existing IT networks and you can add the optional SafeCount Plus cloud platform for remote management and reporting.
“The Irisys SafeCount dashboard puts real-time occupancy data in the hands of attendants and managers while the historical reports provide an audit trail for social distancing compliance,” said Mike Slevin, director of sales at Irisys “Perhaps more importantly, SafeCount gives customers, employees, and visitors peace of mind that your company is protecting their health and safety.”
The SafeCount Plus cloud platform supports an unlimited number of buildings in different locations and time zones. Its advanced reporting enables managers to easily review, compare and analyze occupancy data to identify locations that are not complying with occupancy restrictions, allowing them to take action.
For more information on Irisys SafeCount Live Occupancy Monitoring, visit: https://www.irisys.net/products/safecount-occupancy-monitoring-solution .
About Irisys
Infrared Integrated Systems Ltd, generally called Irisys, is the largest global provider of people counting and real-time queue management solutions. The company’s technology is use by major organizations globally in sectors varying from retail, banks, transport to leisure facilities and public buildings. The systems give operators an unprecedented insight into their business, giving them the information they need to improve customer service, operational efficiency, and profitability. Companies often find opportunities for rapid improvements in their business, and a quick return on investment.
In 2012, Irisys became part of the Fluke Corporation , a worldwide leader in calibration and handheld test instruments. Fluke is world famous for the durability of its test tools and offers a range of tough electrical test tools, infrared thermometers, thermal imagers, and other devices designed for extreme field use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005318/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
